“…Over the past years, numerous studies have focused on B1R and B2R manipulation (inhibition and/or activation) as therapeutic targets in the treatment of different brain disorders such as temporal lobe epilepsy (Arganaraz, Silva et al 2004), spinal cord injury (Xu, Kitada et al 2006, Xu, Gu et al 2008, Yan-Feng, Gang et al 2008), Alzheimer’s disease (Huang, Lin et al 1995, Nitsch, Kim et al 1998, Jong, Ford et al 2003, Prediger, Medeiros et al 2008, Lacoste, Tong et al 2013, Passos, Medeiros et al 2013), ischemic stroke (Xia, Yin et al 2004, Xia, Smith et al 2006, Austinat, Braeuninger et al 2009, Liu, Zhang et al 2009, Scholler, Feiler et al 2011, Woodfin, Hu et al 2011, Waldner, Baethmann et al 2012, Danielisova, Gottlieb et al 2014) TBI (Narotam, Rodell et al 1998, Gorlach, Hortobagyi et al 2001, Zausinger, Lumenta et al 2002, Hellal, Pruneau et al 2003, Ivashkova, Svetnitsky et al 2006, Liu, Zhang et al 2009, Woodfin, Hu et al 2011, Waldner, Baethmann et al 2012, Albert-Weissenberger, Siren et al 2013), and febrile illness (Soares, Santos et al 2017). Nevertheless, the results obtained were controversial.…”